<DOC>
	<DOCNO>NCT00915200</DOCNO>
	<brief_summary>The study design test combination two potent antioxidant nutritional supplement , N-acetylcysteine milk thistle extract silibin , capable correct shed urine protein , oxidative stress , inflammation patient type 2 diabetes mellitus diabetic kidney disease .</brief_summary>
	<brief_title>N-Acetylcysteine Milk Thistle Treatment Diabetic Nephropathy</brief_title>
	<detailed_description>Oxidative stress GSH imbalance major contributor pathogenesis diabetic nephropathy . Current option treatment oxidative stress diabetic nephropathy limit partially effective , thus interest development new strategy high . The study intend test hypothesis combine oral supplementation antioxidant N-acetylcysteine ( NAC ) milk thistle flavonolignan silibin ( silibin-phosphatidylcholine ) reduce proteinuria urinary systemic manifestation oxidative stress inflammation , characteristically observed patient type 2 diabetes mellitus relate nephropathy . We expect effect achieve minimal side effect , good patient tolerance . The trial design two-center , double-blind , placebo-controlled , randomize , modified-factorial dose-ranging design , five-arm pilot study patient Type 2 diabetes mellitus advance diabetic nephropathy proteinuria . Intervention consist three-month oral administration NAC , silibin , and/or respective placebo three month . Subjects randomize follow five intervention arm : ( A ) placebo ; ( B ) NAC ; ( C ) silibin ; ( D ) NAC + silibin ; ( E ) NAC + double-dose silibin . The primary outcome measure urinary excretion albumin , marker glomerular injury . Secondary outcome measure alpha-1 microglobulin , marker tubular injury , urinary excretion inflammatory cytokine C-C chemokines , i.e . marker renal inflammation . In addition , peripheral blood monocyte patient analyze glutathione ( GSH ) content activity GSH metabolizing enzyme . All outcome measure monitor relation treatment allocation prevalent blood urine level active treatment . Safety tolerability combination treatment monitor throughout trial .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Silybin</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>Males female , age 1870 year old . Type 2 diabetes mellitus Diabetic nephropathy , define : estimate GFR 60 15 ml/min , presence proteinuria . Current medical treatment low dose aspirin Treatment hypertension ( limit ) one diuretic , one beta blocker one medication class ARBs ACE inhibitor . Treatment hyperglycemia ( limited ) glipizide medication class insulin . Treatment hypercholesterolemia ( limit ) one medication class statin . Type 1 diabetes mellitus . Glycosylated hemoglobin ( HbA1C ) &gt; 10 % &gt; 20 % variation estimate GFR , last 6 month SBP &gt; 170 mmHg DBP &gt; 100 mmHg medication Other secondary form hypertension ( endocrine , renovascular ) History intolerance : Both ACEI ARBs ; The investigational supplement ; Iodinated radiologic contrast material . Known non diabetic renal disease , history solid organ transplantation . Hepatitis virus Human Immunodeficiency virus infection Use one follow medication within 2 month prior enrollment study : Metformin . Thiazolidinediones ( pioglitazone rosiglitazone ) ; Prescriptiongrade vitamin E , vitamin C , systemic steroid , and/or nonsteroidal antiinflammatory agent ; Overthecounter vitamin E , vitamin C , and/or nonsteroidal antiinflammatory agent . Overthecounter antioxidant supplement include : Lipoic acid , Coenzyme Q10 , Nacetylcysteine ( NAC ) , Glutathione ( GSH ) , Chromium , Fishoil extract ( omega3 fatty acid ) , Soy extract ( isoflavones ) , Milk thistle extract ( silymarin ) , Greentea preparation , Pomegranate extract , Grape extract , Prickly pear extract . Active coronary artery disease cerebral vascular disease within 3 month prior sign inform consent . Hepatic dysfunction define abnormal total bilirubin liver enzyme ( ALT , AST ) &gt; 2 time upper limit normal range . Active malignancy . History drug alcohol dependency . Psychiatric neurological condition , prevent aware consent study and/or adherence study protocol Unwillingness practice birth control throughout study . Participation another clinical study within 1 month prior sign inform consent form . Planned move outside study area , surgery radiographic study utilize iodinebased contrast material within next one year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diabetic Nephropathies</keyword>
	<keyword>Proteinuria</keyword>
	<keyword>Renal Insufficiency , Chronic</keyword>
	<keyword>Monocytes</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Silymarin</keyword>
	<keyword>Acetylcysteine</keyword>
	<keyword>Dietary Supplements</keyword>
	<keyword>Complementary Therapies</keyword>
</DOC>